Effect of F. Prausnitzii on Glycemic Control

Exclusion Criteria

• •Other reasons for liver inflammation e.g. hepatitis A, hepatitis B, hepatitis C, HIV-positive, confirmed or suspected cirrhosis, Wilsons disease, autoimmune hepatitis, hemochromatosis, alcohol related fatty liver or pancreatitis, laboratory screen AST/ALT \>2 (ULN), Bilirubin \>1 (ULN)
• •Heart failure NYHA class III, cardiovascular event within 6 months, unstable angina pectoris
• •Diabetes mellitus, HbA1c \>47 mmol/mol or fp-Glucose \>6.9 mmol/L on 2 occasions
• •Chronic obstructive pulmonary disease and asthma treated with intermittent steroids to be under control
• •Blood pressure \>170/105 mmHg
• •Blood donation \>500 mL blood \<3 months before screening
• •Anemia, Hb \<117 g/L females and Hb \<134 g/L males; leukopenia, LPK \<3.5x1E9/L, ongoing infection CRP \>10 mg/L
• •Hyperthyroidism, T4 \>22 nmol/L or hypothyroidism, TSH \>4,2 mIU/L
• •Laboratory result of clinical significance meaning that participation in the study is unsuitable according to Investigator
• •Calculated glomerular filtration rate (GFR) \<60 mL/min/1.73 m2
• •Cancer \<5 years since diagnosis, except for basal-cell carcinoma
• •Treatment during the last 3 months with oral steroids, biological drugs, immunosuppressive drugs, e.g. cyklosporin, drugs known to cause liver damage or to be liver toxic
• •Bariatric surgery
• •Antibiotic treatment during the last 3 months or reoccurring antibiotic treatment \>3 times a year
• •Regular or sporadic use of probiotic product (not food containing probiotics) during the last 3 months
• •Confirmed IBD, irritable bowel syndrome (IBS), bile acid malabsorption, gastrointestinal infections during the last 3 months or any experienced problems from the gastrointestinal tract during the last month that the Investigator expect could influence the participation in the study
• •Allergy to metronidazol, the adhesive glue for the CGM sensor, milk protein
• •Smoking \>10 cigarettes/day
• •Alcohol consumption, \>7 units/week females, \>14 units/week males
• •Use of narcotics e.g. cannabis, amphetamine (not medical use), hallucinogens, gamma-hydroxybutyric acid
• •Pregnancy, breast-feeding or planned pregnancy
• •Participation in other studies except IGT2